James D Levine MD
Myeloproliferative Disorder Hematology-Oncology
Assistant Professor of Medicine, Beth Israel Deaconess Medical Center
Join to view full profile
330 Brookline AveScc913Boston, MA 02215
Phone+1 617-667-9235
Dr. Levine is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Levine is a hematology specialist in Boston, Massachusetts with subspecialties in Myeloproliferative Disorder Hematology-Oncology. He completed his medical education at the University of California San Francisco School of Medicine in 1976, followed by residencies and fellowships in Internal Medicine and Hematology and Medical Oncology. He currently serves as the Clinical Director of the Bone Marrow Transplant/Hematologic Malignancy Service at Beth Israel Deaconess Medical Center. Dr. Levine has extensive experience in conditions including non-hodgkin lymphoma, thrombocytosis, and polycythemia vera. He has contributed significantly to the field through multiple publications in reputable journals and participation in clinical trials. He has been recognized for his work, receiving honors such as a Regional Top Doctor award from Castle Connolly in 2014.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1979 - 1982
University of California (San Francisco)Residency, Internal Medicine, 1977 - 1979
Detroit Medical Center/Wayne State University (Sinai Grace)Internship, Internal Medicine, 1976 - 1977- University of California San Francisco School of MedicineClass of 1976
University of CaliforniaMS, Medical Sciences, 1972 - 1974
Certifications & Licensure
CA State Medical License 1977 - Present
MA State Medical License 1983 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2017
- CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012-2017
- CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2017
Clinical Trials
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
- Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01
- A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 11 citationsClinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipien...Nitipong Permpalung, Monica V Mahoney, Christopher McCoy, Amporn Atsawarungruangkit, Howard S. Gold
Leukemia & Lymphoma. 2019-01-02 - 230 citationsProspective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Pa...Robert J. Soiffer, Haesook T. Kim, Joseph P. McGuirk, Mitchell E. Horwitz, Laura Johnston
Journal of Clinical Oncology. 2017-10-17 - 147 citationsMUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemiaAthalia Rachel Pyzer, Dina Stroopinsky, Hasan Rajabi, Abigail Washington, Ashujit Tagde
Blood. 2017-03-30
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
